Latest Period
Q1 2026
Security Snapshot
Vivos Therapeutics, Inc. - Common Stock, par value $0.0001 per share (VVOS) Institutional Ownership
CUSIP: 92859E207
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
23
Shares (Excl. Options)
1,822,361
Price
$1.18
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- VVOS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 1,822,361
- Total 13F value
- $2,146,963
- Portfolio coverage rank
- 0%
- Share change
- +1,164,268
- Value change
- +$1,275,697
- Number of holders
- 23
- Shares outstanding
- 13,492,854
- SEC-reported price per share
- $0.67
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VVOS - Vivos Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 92859E207.
- 23 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 18 to 23 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,335,932 to $2,146,963.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 23 institutions filings for Q1 2026.
Security key
92859E207
Latest holder period
Q1 2026
13F holders
23
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
VVOS full holder history
Vivos Therapeutics, Inc. SEC filings
Vivos Therapeutics, Inc. company facts
Vivos Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92859E207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
VVOS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| V-Co Investors 3 LLC | 20% | $3,585,844 | 2,696,123 | Michael C. Skaff | 31 Mar 2026 | |||
| V-CO Investors LLC | 20% | +100% | $4,188,594 | +$2,583,360 | 1,342,498 | +161% | SP Manager LLC | 09 Jun 2025 |
| ARMISTICE CAPITAL, LLC | 8.3% | $1,339,031 | 1,115,859 | Armistice Capital, LLC | 31 Mar 2026 | |||
| LUO DAWEI | 8.5% | $3,432,096 | 572,016 | Dawei Luo | 08 Jul 2025 | |||
| INTRACOASTAL CAPITAL, LLC | 5% | $796,804 | 297,315 | Mitchell P. Kopin | 22 Dec 2024 |
As of 31 Mar 2026, 23 institutional investors reported holding 1,822,361 shares of Vivos Therapeutics, Inc. - Common Stock, par value $0.0001 per share (VVOS). This represents 14% of the company’s total 13,492,854 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
14%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 8.3% | 1,115,859 | 0.04% | $1,316,714 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2% | 273,329 | 0% | 0% | $322,528 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.71% | 95,543 | +70% | 0% | $112,740 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.31% | 42,500 | +4.9% | 0% | $50,150 |
| IHT Wealth Management, LLC | 0.3% | 41,061 | 0% | $48,452 | |
| B. Riley Wealth Advisors, Inc. | 0.28% | 38,066 | -13% | 0% | $41,492 |
| Centurion Wealth Management LLC | 0.26% | 35,684 | 0.01% | $42,108 | |
| VANGUARD FIDUCIARY TRUST CO | 0.23% | 30,832 | 0% | 0% | $36,382 |
| BlackRock, Inc. | 0.21% | 27,817 | 0% | 0% | $32,824 |
| XTX Topco Ltd | 0.19% | 25,117 | 0% | $29,638 | |
| STATE STREET CORP | 0.18% | 24,922 | 0% | 0% | $29,408 |
| Sequoia Financial Advisors, LLC | 0.18% | 24,000 | 0% | $28,320 | |
| Acorn Wealth Advisors, LLC | 0.11% | 14,776 | 0% | 0.01% | $17,436 |
| NORTHERN TRUST CORP | 0.09% | 12,511 | 0% | 0% | $14,763 |
| UBS Group AG | 0.08% | 11,046 | -13% | 0% | $13,035 |
| Tower Research Capital LLC (TRC) | 0.05% | 7,388 | +149% | 0% | $8,718 |
| OSAIC HOLDINGS, INC. | 0.01% | 1,143 | 0% | 0% | $1,348 |
| SIGNATUREFD, LLC | 0% | 547 | 0% | 0% | $645 |
| Blue Trust, Inc. | 0% | 160 | 0% | 0% | $189 |
| Kozak & Associates, Inc. | 0% | 49 | 0% | 0% | $60 |
| MORGAN STANLEY | 0% | 7 | 0% | 0% | $8 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 0% | 3 | 0% | $4 | |
| CITIGROUP INC | 0% | 1 | 0% | 0% | $1 |
| DRW Securities, LLC | 0% | 0 | -100% | $0 | |
| BANK OF AMERICA CORP /DE/ | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,822,361 | $2,146,963 | +$1,275,697 | $1.18 | 23 |
| 2025 Q4 | 658,093 | $1,335,932 | -$421,186 | $2.03 | 18 |
| 2025 Q3 | 686,727 | $2,129,135 | +$875,070 | $3.10 | 22 |
| 2025 Q2 | 402,082 | $1,271,158 | +$424,559 | $3.16 | 18 |
| 2025 Q1 | 281,633 | $802,423 | -$1,021,557 | $2.85 | 19 |
| 2024 Q4 | 466,818 | $2,003,111 | +$1,082,494 | $4.29 | 19 |
| 2024 Q3 | 245,048 | $630,697 | +$156,010 | $2.61 | 22 |
| 2024 Q2 | 186,896 | $433,846 | -$444,091 | $2.22 | 18 |
| 2024 Q1 | 133,960 | $646,578 | -$323,172 | $4.83 | 13 |
| 2023 Q4 | 250,612 | $3,117,234 | +$3,117,234 | $12.44 | 14 |